Genetic Technologies (STU:DU8) Scaled Net Operating Assets : N/A (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genetic Technologies Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genetic Technologies's operating assets for the quarter that ended in Dec. 2023 was €2.91 Mil. Genetic Technologies's operating liabilities for the quarter that ended in Dec. 2023 was €2.01 Mil. Genetic Technologies's Total Assets for the quarter that ended in Sep. 2023 was €0.00 Mil. Therefore, Genetic Technologies's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was N/A.

Genetic Technologies Scaled Net Operating Assets Historical Data

The historical data trend for Genetic Technologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Scaled Net Operating Assets Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.06

0.08

0.06

0.24

0.17

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Genetic Technologies's Scaled Net Operating Assets

For the Diagnostics & Research subindustry, Genetic Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's Scaled Net Operating Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Scaled Net Operating Assets falls into.

Genetic Technologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genetic Technologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(4.34	-	1.958)	/	13.829
=	0.17

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	9.203	-	4.863
=	4.34

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.288	-	0.142	-	0.188
=	1.958

Genetic Technologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(2.908	-	2.008)	/	0
=	N/A

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.197	-	2.289
=	2.908

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.243	-	0.052	-	0.183
=	2.008

Genetic Technologies Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (STU:DU8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

GENE:USA GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines